2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide

• ChemBase编号: 409
• 分子式: C20H29N3O2
• 平均质量: 343.46316
• 单一同位素质量: 343.22597718
• SMILES: O(c1nc2c(c(C(=O)NCCN(CC)CC)c1)cccc2)CCCC
• Canonical SMILES: CCCCOc1nc2ccccc2c(c1)C(=O)NCCN(CC)CC
• InChI: InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
• InChIKey: PUFQVTATUTYEAL-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
• IUPAC传统名: dibucaine
• 商标名: Cinchocaine; Cinchocaine HCL; Dermacaine; Dibucain; Dibucaine base; Dibucaine hydrochloride; Heavy Solution Nupercaine; Nupercainal; Nupercaine; Sovcaine; cinchocaine hydrochloride
• 别名: 狄布卡因; Dibucaine; CINCHOCAINE; Dibucaine

登记号

• CAS号: 85-79-0
• EC号: 201-632-1
• MDL号: MFCD00047595
• PubChem SID: 24893238; 160963872; 46506734
• PubChem CID: 3025
• CHEBI ID: 247956
• ATC码: D04AB02; N01BB06; S02DA04; S01HA06; C05AD04
• CHEMBL: 1086
• Chemspider ID: 2917
• DrugBank ID: DB00527
• KEGG ID: D00733
• 美国药典/FDA物质标识码: L6JW2TJG99
• 维基百科标题: Dibucaine

理论计算性质

JChem

• Acid pKa: 14.57441
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 0.47672126
• LogD (pH = 7.4): 2.0500696
• Log P: 3.6981626
• 摩尔折射率: 102.121 cm^3
• 极化性: 40.42192 Å^3
• 极化表面积: 54.46 Å^2
• 可自由旋转的化学键: 10
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.79
• LOG S: -3.95
• 溶解度: 3.89e-02 g/l

分子性质

理化性质

• 溶解度: 42 mg/L
• 疏水性(logP): 4.2

安全信息

• RTECS编号: GD3150000
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22-41
• 安全公开号: 26-39
• GHS危险品标识: GHS05; GHS07
• GHS警示词: Danger
• GHS危险声明: H302-H318
• GHS警示性声明: P280-P305 + P351 + P338
• 个人保护装置: dust mask type N95 (US), Eyeshields, Faceshields, Gloves

药理学性质

• 给药途径: topical, intravenous (equine euthanasia)

产品相关信息

• 级别: analytical standard

详细说明

MP Biomedicals - 05201127

MP Biomedicals Rare Chemical collection

DrugBank - DB00527

• Drug Groups: approved
• Description: A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
• Indication: For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
• Pharmacology: Dibucaine is an amide-type local anesthetic, similar to lidocaine.
• Toxicity: Subcutaneous LD₅₀ in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
• Affected Organisms: Humans and other mammals
• Biotransformation: Primarily hepatic.
• Absorption: In general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation.
• References: Abdel-Ghani NT, Youssef AF, Awady MA: Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry. Farmaco. 2005 May;60(5):419-24. [Pubmed] ; Souto-Padron T, Lima AP, Ribeiro Rde O: Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi. Parasitol Res. 2006 Sep;99(4):317-20. Epub 2006 Apr 13. [Pubmed] ; Nounou MM, El-Khordagui LK, Khalafallah N: Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm. 2005 Sep-Oct;62(5):369-79. [Pubmed]
• External Links: Wikipedia; Drugs.com

Sigma Aldrich - D0513

Frequently Asked Questions
Live Chat and Frequently Asked Questions are available for this Product.
Biochem/physiol Actions
强效、长效局部麻醉剂
Other Notes
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. D0513.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

参考文献

• Abdel-Ghani NT, Youssef AF, Awady MA: Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry. Farmaco. 2005 May;60(5):419-24. Pubmed
• Souto-Padron T, Lima AP, Ribeiro Rde O: Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi. Parasitol Res. 2006 Sep;99(4):317-20. Epub 2006 Apr 13. Pubmed
• Nounou MM, El-Khordagui LK, Khalafallah N: Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm. 2005 Sep-Oct;62(5):369-79. Pubmed